Lutetium-177 prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys. Here we report three cases of radiation nephropathy with severe chronic kidney disease induced by renal thrombotic microangiopathy following extensive treatment with Lu-PSMA radioligand therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2022.05.025 | DOI Listing |
Publication Analysis
Top Keywords
lu-psma radioligand
12
radioligand therapy
12
radiation nephropathy
8
renal thrombotic
8
extensive lu-psma
4
therapy lead
4
lead radiation
4
nephropathy renal
4
thrombotic microangiopathy-like
4
microangiopathy-like picture
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!